Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I keep telling you all but no-one wants to listen. There's gotta be a fundraising in the works and I'll bet anything that's the next news we'll get. If I'm right I just hope there's a justifiably good reason for diluting shareholders at these crap levels.
Isn't it obvious? It's as clear as daylight to me at least that there must be a fundraising going on and it's in the buyer or buyers' interest to keep the market price from going up right now so they can get the placing shares at a good price. I just can't think of anything else that makes sense and fits the action we're seeing right now. Only thing is what would BOCX want more money for right now??
If you ask me, the current price manipulation plus the lack of publicity surrounding the Inverness deal has all the hallmarks of a fundraising in progress. It is obviously inconvenient for someone for the price to rise at the moment. It is obviously being held back for a reason. Just my 2c from a long-term shareholder.
Erthang, Respect man (kneeling down bowing profusely) !!! Many thanks and kudos for a thoroughly professional job. I have pencilled you in (with partner) for the stately Bernini Suite at the Bernini Hotel in Rome when we all get together there to celebrate a +$20 share price in a few years' time!! You get the Pope's suite on da house - he can cycle it over from the Vatican, I'm sure he won't mind :))
Respect!
merovingian
Good stuff Kag, it's a well-documented and oft repeated fact how badly the PSA test essentially 'sucks'. It is truly indicative of the dearth of credible alternatives that the medical community ever adopted this totally undependable test in this particular area of cancer. Might as well toss a coin!
Totally agree with your assertions here. PSA is on the way out and Abbott knows they're racing against time to come out with an enhancement or alternative in order to secure their lucrative market position. RECAF could well be their salvation...and our holy grail!
Not too sure that at their ages a nice check of upwards of $10 million wouldn't be in their best interests Headache - financial security for the rest of their lives and the funds to enable them to pursue other scientific research/pursuits etc could be high on their list of life priorities, n'est-ce pas?
Regards,
merovingian
Kag, you certainly raise some interesting points here.
Re your first one, I don't believe the prevailing share price would/should hinder an outright sale if that is what both parties agreed to pursue, for two reasons : (a) a BOCX announcement that such talks were being held (I believe it is mandatory to inform the market in such event) would put paid to that in a flash!!; and (b) even without such announcement, the exercise would be one of valuing Biocurex on its patents' future market worth and arriving at a valuation accordingly,irrespective of prevailing price in the market. That the market is assigning a totally incorrect valuation to BOCX is an extraneous matter in my opinion and I don't believe there is any market rule that says a company can't be taken out for 10/20 times its current market price. If Abbott wanted the company they're obviously not going to offend/insult Biocurex by offering some cheap take-out price -they won't pussy-foot around, they'd have done the numbers and it'd be way too valuable for them to risk losing out.
As to your second point that the royalty route is much more likely, whilst not necessarily disagreeing over this likelihood, is it not just as feasible that Abbott might consider it more advantageous to them to pay a (big for Biocurex,not so large in Abbott's eyes)one-time price now to own the patents outright than to pay out an increasingly fatter check for several years that would cost them much more over time (especially if they can see numerous areas to exploit the patents over)?
Incidentally, does anyone know the length of time of the granted patents and those being filed??
Very interesting insight re the Pliva story btw, makes one drool in anticipation of what could be expected here!
Looking forward to your further considered comments,
merovingian
Steelcitydog,
Many thanks for your warmth - it's good to be here amongst fellow shareholders whilst we await the promised land to materialise. I'm glad to see my suggestion of Rome as a possible destination for all us BOCXers to meet up and have a well-deserved celebratory weekend party has sparked some folks' imagination here - it'd certainly be a great place to meet up and blow some of our new-found wealth! All in good time of course....meanwhile we must endeavour to keep up the dd and our collective feet on the ground!
Hey hope you have a great time in Maui - a different world to meravigliosa Roma but the Mrs. obviously has taste!
All the best,
merovingian
Kag, there is no question in my mind that if Abbott are forming the opinion that RECAF is really all it is made out to be, then they would want it exclusively all to themselves. I would venture further out on a limb and say that not even an exclusive licence would do....they would want to OWN it outright or at the very least take a rather large significant strategic stake in the business. This is another possible scenario that is quietly being hammered out in the background. What do you think?
Headache, I simply can't believe that Biocurex, having already,by their own public admission at the time, been pretty advanced in negotiations with around 3 other potential licensees at the same time as Abbott (we are talking over 2 years ago now), have not succeeded in finalising any other license agreements with those other firms in all this time! There's got to be something behind it and I reckon that something is an understanding/undertaking they've got with Abbott. That's my take and the more time that passes the more it will take to convince me otherwise. Time will tell I suppose. Thanks for your input.
Thanks all for your considered comments and input. At least you've made me feel I'm not necessarily on my way to the mental institution yet!! Sure it's only speculation of course and we'll never know until and if that particular scenario were to pan out...BUT..what I do in these situations is to try and put myself in the CEO's chair and ponder over an exit route that would be a winner all round. And I think licensing your technology exclusively to one of the world's leading diagnostic powerhouses who would commit themselves to commercialise your tech in several markets that they either dominate or have a high market share in, must figure pretty highly in his thinking. Of course there's pros and cons with both the single licensee and multi-licensee routes and arguments can be drawn up in favour and against either. As a shareholder though I certainly would be happy (no,make that pretty ecstatic!) if Abbott stepped up to the plate and signed an exclusive multi-year deal with us to exploit the tech in all its applications and in several markets.
I guess it really depends in a big way on how Abbott have been progressing since they signed up. From what we know it appears that the feedback is very positive to date. Obviously these things take time as a serious organization like Abbott would ensure they proceed at a pace that meets their meticulous and exacting high standards - they won't rush it to suit our agenda.
So we wait with bated breath and high hopes. My gut feeling is that we will be extremely well rewarded for our patience and endurance.
Fingers crossed and sincere wishes for good luck to us all!
merovingian
P.S. OT - I had a very good laugh at references to the Da Vinci Code conjured up by my handle! Please don't get carried away though - I may be made in the image of Christ as are we all but I'm certainly not in His bloodline or anything so exotic lol so I thought I'd better dispel that one here straight off!! Incidentally, the Da Vinci Code is a great thriller but don't read anything else into it - it is in fact very badly researched and littered with inaccuracies. But a fantastic read and I'm sure it will make a great film too. My personal favorite of Dan Brown is Angels and Demons - it just edges DaVinci I felt and what really made it for me is that it's set in Rome, a city I love and know very well. In fact I've actually stayed at the Bernini Hotel off Piazza Barberini mentioned in the book's final chapter so that really tickled me no end!! I propose that when BOCX hits the lofty price of $10 in due course we all rent out the hotel's penthouse suites for a couple of nights and have a big party having attained our own quest for the holy grail!!! Dr.Moro and the Pope can be guests of honour lol
I have a theory, comments/discussion most welcome.
I've been a holder of a decent size of Biocurex shares for a few years now. I rarely post - in fact, I think I only ever posted once or twice a couple of years ago! But I have always kept a close eye on the company and its developments and remain totally committed, supportive and excited.
It's struck me as very strange that we have had two obvious long-awaited developments that have not materialised. Firstly, the re-listing of the shares onto the OTC-BB or better (AMEX, Nasdaq Small-cap etc) and secondly, further licensing deals following the Abbot coup. Both events were forecast by management on more than one occasion these last couple of years. Obviously things always seem to take much longer to pan out for a multitude of reasons but it seems here to be taking an awfully much longer time than would be considered reasonable. I am sure most fellow shareholders would agree with me.
I am beginning to think that there may be more going on here than is readily apparent. These are my thoughts for what they're worth :
Remember that Biocurex awarded Abbot a semi-exclusive license so that they could pursue the same type of deal with other large and medium-sized companies they said then that they were well down the road in negotiating with. Now we all know that a lot of time has passed since we signed up with Abbot and no other licencing deals have been signed. Hmmmm. And also, despite noises to the contrary on several occasions, we're still on the pinks. Is it possible to conclude, I wonder, that the feedback from Abbot is so good to the extent that Abbot don't want their competitors to get in on this technology and they've basically signalled to Biocurex : 'give us some time to fully test this, step back from signing any other deals for an agreed period, then we'll upgrade our deal with you to a fully exclusive license for which we'll pay you $x million upfront and a more generous royalty going forward'. The $x million upfront would satisfy the conditions for an AMEX or other share listing and/or facilitate an institutional placing at a greatly enhanced price level on the back of this great deal. So, two birds hit with one stone and this might explain why both overdue developments haven't materialised.
Do any of you long-termers here buy this possible explanation? From where I stand it certainly appears plausible, but hey, what do I know?!! Comments/discussion most welcome, thanks.
All the best,
merovingian
Does anyone know if the previously-advertised April 10th BusinessTV interview with Biocurex went ahead or not? No-one seems to have mentioned it and it's not appearing on B-TV's website either.
Cheers,
merovingian
Thx Bocxman, but WHO exactly has authored the research report then? Tia, merovingian.
Bocxman, do I take it that YOU wrote this report? If not, who did as there is no reference to an author. Thanks.
What we need now is for BOCX to move off the pinks and get re-quoted on the BB. Wonder how long that's going to take? Anyone got an idea?
Merovingian
A340 fair comment, thanks.
Whilst it's impossible to be in a position to know exactly what is going on with any company, it's always a good idea to dig as much as possible to increase the knowledge base and thus minimise the perceived risk with an investment. However, at the end of the day, you need to go with your gut feeling - this is where I am at with BOCX.
I'm more than ready to give the benefit of the doubt to the company when I weigh up all the events and circumstances. I shall be maintaining my position but won't add further until the dust settles a bit more and I can be confident that the whole debacle is truly behind them for good - even if it means paying more in time but with more certainty that their long-term future is secure.
Let's keep an active discussion going - we all stand to benefit from it.
Merovingian
Hi A340,thanks for your reply. I have no problem viewing the potential upside here (which you have adequately covered in your reply) and agree that basically the sky's the limit when attempting a future valuation exercise.
I also agree with your implication that the downside is probably 100% of the investment if all goes pear-shaped. It is exactly this aspect of the equation that I was trying to determine in my previous post - assessing the downside risk here as much as possible to try and build up a 'comfort zone' with this investment. So, specifically :
1. do you think/have an insight or knowledge that the SEC is done for good or might they still come up with a formal charge or charges? I suspect we won't know until it hits,if it does.What's your take?;
2. could there potentially be class action lawsuits in future or would we have seen them already? There has so far not been any indication of wrong-doing on the company's part (e.g. insider dealing, having a part in the previous spamming exercise etc)so I'm hoping they come out of this smelling of roses. But who am I to know? Have you got a view?
Appreciate your feedback.
Cheers,
Merovingian
A340/others, your comments/insight appreciated...
Hi all, this is my maiden post here. I have been long BOCX since last year and accumulated most of my stake around the 25c level so the damage so far has been more of the loss-of-profit type than actual loss incurred.
I invested 'cos I liked the story and thought (and still do) that the tech has a lot of merit and potential. Obviously, it has been very disappointing to say the least to see what has happened to the share-price since last April. Whilst I put the blame largely at the door of unscrupulous shorters and the effects of aggressive spamming, I must admit that certain previous disclosures by the company may have been slightly over-zealous and prompted the FDA/SEC to take the action they did...with the unfortunate repercussions suffered by us investors.
The question now is : is this a classic buying opportunity staring us in the face or could there be yet more fall-out to follow? I draw a lot of comfort from the fact that there have been no class action lawsuits in the wake of the SEC action as has happened recently with other biotechs ( take a look at VAPH and BPUR for instance). But does this mean they might not follow in future? In the cases mentioned above, they were instantaneous - occurring in days - so the BOCX situation must be much more encouraging, I suppose? Also, we can't be sure that the SEC is done - even if they're satisfied with the resultant re-wording of past claims etc they won't say anything as they are not obliged to issue any statement ( which I think is most unfair by the way). So where does that leave us?
I would genuinely be interested in fellow investors' views as I'd like to be able to assess the current risk as best as possible. Thanks in advance to anybody who responds - I'd love nothing more than to have a proper discussion with like-minded investors.
Merovingian